Westminster Health Forum

Assessing priorities for NICE: funding, quality and the Life Sciences Industrial Strategy

Morning, Thursday, 11th January 2018

Central London

THIS EVENT IS CPD CERTIFIED



This seminar will be a timely opportunity to assess priorities for NICE in health and social care.


Following the Government’s response to the Accelerated Access Review, delegates will examine the future role of NICE in improving access to new treatments, medical technologies and diagnostic tools, as well as its engagement with the Life Sciences Industrial Strategy.


Attendees will also discuss key issues for funding NICE and the delivery of its Business Plan; lessons learnt from the new approach to the appraisal and funding of cancer drugs - with medicines moving from the Cancer Drugs Fund to routine NHS use - as well as reforms to health technology appraisals and the Highly Specialised Treatments programme, following the subsequent ABPI application for a Judicial Review.


Further sessions will consider the next steps for increasing patient and public involvement, following research carried out to capture patient perspectives; the developing role of NICE guidelines in health and social care and the wider impact of NICE outside of England.



Guests of Honour

Professor Gillian Leng

Deputy Chief Executive and Director of Health and Social Care, NICE

Professor Carole Longson

Director, Centre for Health Technology Evaluation, NICE

Guests of Honour

Professor Carole Longson

Director, Centre for Health Technology Evaluation, NICE

Professor Gillian Leng

Deputy Chief Executive and Director of Health and Social Care, NICE

Keynote Speakers

Dr Liz Mear

Chair, The AHSN Network and Chief Executive, The Innovation Agency - Academic Health Science Network for the North West Coast

Dr Alan MacDonald

Chair, Scottish Medicines Consortium and Consultant Rheumatologist, NHS Grampian

Dr Stuart Dollow

Founder, Vermilion Life Sciences; Head of Global Clinical Development and Medical Affairs, UCB and Member, Expert Advisory Group, Accelerated Access Review

Chair

Baroness Morgan of Drefelin

Chair, National Cancer Research Institute and Chief Executive, Breast Cancer Now

Speakers

Rosemarie Finley

Chief Executive Officer, Myeloma UK

Dr Richard Torbett

Executive Director, Commercial, ABPI

Dr Felix Greaves

Deputy Director, Science and Strategic Information, Public Health England